The company along with its subsidiaries has overall bed capacity of 8800+ beds as on 30th September, 2025
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
With this expansion, the overall fermentation capacity of the company has increased from 450 KL to 990 KL
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Extended lab space for product development, customer demos, and training
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
Akums invested Rs. 272 crore in capital expenditure during FY25
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
Scores highest PAT of Rs. 118 crore in FY25
Subscribe To Our Newsletter & Stay Updated
